Biotechnology

Hoth Therapeutics files patents for a therapy to mitigate severe skin reactions from cancer treatments, a strategic move that could transform patient care.

BridgeBio Pharma hosts a key investor webinar on its oral drug infigratinib for achondroplasia, setting the stage for crucial trial results in Q1 2026.

Fresh off a major drug approval, Insmed's upcoming J.P. Morgan talk is under scrutiny as investors eye pipeline updates and acquisition potential.

Ironwood Pharma forecasts a massive profit jump by lowering its top drug's price, a bold move as it advances its rare disease pipeline for future growth.

With patent cliffs looming and big bets on M&A, all eyes are on BMS to prove its growth strategy and high-stakes pipeline can deliver in 2026.

The strategic separation of MarathonLS into two specialized firms aims to boost growth and service in the competitive life sciences support sector.

Samsung Bioepis is now directly selling its Lucentis biosimilar in Europe, a move set to increase competition and improve access to vital eye disease treatments.

Neovii Pharmaceuticals names Frédéric Prince its next CEO, bringing deep oncology and gene therapy experience from Roche to steer its next growth phase.

South Korea's KLMBio is accelerating its global push with major investments in production and new products to capture the booming regenerative medicine market.

AI drug discovery firm Insilico Medicine soars in its Hong Kong debut, the city's largest biotech IPO of 2025, validating a new tech-driven era for medicine.

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

As 10x Genomics preps for its J.P. Morgan spotlight, investors seek a clear path to profit amid fierce competition and groundbreaking innovation.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Emmaus Life Sciences outsources its sickle cell drug Endari® in North America to focus on global growth, as NeoImmuneTech gains a key U.S. market foothold.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.

Oncodesign Precision Medicine and Navigo Proteins end their radiotheranostics pact, shifting focus to internal programs amid high-stakes R&D challenges.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.